MX2022007628A - Combinaciones. - Google Patents
Combinaciones.Info
- Publication number
- MX2022007628A MX2022007628A MX2022007628A MX2022007628A MX2022007628A MX 2022007628 A MX2022007628 A MX 2022007628A MX 2022007628 A MX2022007628 A MX 2022007628A MX 2022007628 A MX2022007628 A MX 2022007628A MX 2022007628 A MX2022007628 A MX 2022007628A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- disease
- treating
- compounds
- condition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940125944 selective estrogen receptor degrader Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952020P | 2019-12-20 | 2019-12-20 | |
| US202063009788P | 2020-04-14 | 2020-04-14 | |
| PCT/US2020/065415 WO2021127047A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007628A true MX2022007628A (es) | 2022-08-25 |
Family
ID=76478122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007628A MX2022007628A (es) | 2019-12-20 | 2020-12-16 | Combinaciones. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230087941A1 (enExample) |
| EP (1) | EP4069240A4 (enExample) |
| JP (1) | JP2023507797A (enExample) |
| KR (1) | KR20220119419A (enExample) |
| CN (1) | CN115038450A (enExample) |
| AU (1) | AU2020407573A1 (enExample) |
| BR (1) | BR112022012280A2 (enExample) |
| CA (1) | CA3165479A1 (enExample) |
| IL (1) | IL294078A (enExample) |
| MX (1) | MX2022007628A (enExample) |
| TW (1) | TW202135809A (enExample) |
| WO (1) | WO2021127047A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| WO2023280180A1 (zh) * | 2021-07-05 | 2023-01-12 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的稠环化合物 |
| TW202340196A (zh) * | 2021-12-31 | 2023-10-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有雜環的化合物及其應用 |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| AU2010247397B2 (en) * | 2009-05-15 | 2012-07-12 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound |
| SG11201607339VA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2020
- 2020-12-16 JP JP2022538218A patent/JP2023507797A/ja active Pending
- 2020-12-16 MX MX2022007628A patent/MX2022007628A/es unknown
- 2020-12-16 US US17/757,486 patent/US20230087941A1/en not_active Abandoned
- 2020-12-16 KR KR1020227024700A patent/KR20220119419A/ko active Pending
- 2020-12-16 CN CN202080095297.8A patent/CN115038450A/zh active Pending
- 2020-12-16 CA CA3165479A patent/CA3165479A1/en active Pending
- 2020-12-16 IL IL294078A patent/IL294078A/en unknown
- 2020-12-16 BR BR112022012280A patent/BR112022012280A2/pt not_active IP Right Cessation
- 2020-12-16 WO PCT/US2020/065415 patent/WO2021127047A1/en not_active Ceased
- 2020-12-16 AU AU2020407573A patent/AU2020407573A1/en not_active Abandoned
- 2020-12-16 EP EP20901281.4A patent/EP4069240A4/en active Pending
- 2020-12-18 TW TW109145140A patent/TW202135809A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3165479A1 (en) | 2021-06-24 |
| KR20220119419A (ko) | 2022-08-29 |
| IL294078A (en) | 2022-08-01 |
| CN115038450A (zh) | 2022-09-09 |
| WO2021127047A1 (en) | 2021-06-24 |
| AU2020407573A1 (en) | 2022-07-14 |
| US20230087941A1 (en) | 2023-03-23 |
| TW202135809A (zh) | 2021-10-01 |
| JP2023507797A (ja) | 2023-02-27 |
| EP4069240A4 (en) | 2023-12-20 |
| BR112022012280A2 (pt) | 2022-08-30 |
| EP4069240A1 (en) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007628A (es) | Combinaciones. | |
| MX2023000025A (es) | Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos. | |
| MX2022007626A (es) | Combinaciones. | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| MX2023008954A (es) | Inhibidores de los receptores erbb. | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| CR20240296A (es) | Inhibidores parp1 | |
| WO2019169065A3 (en) | Wee1 kinase inhibitors and methods of treating cancer using the same | |
| IL290177A (en) | History of 4,2,1-oxadiazol-5-one for cancer therapy | |
| GEP20247627B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| MX2022007623A (es) | Combinaciones. | |
| SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2021010321A (es) | Compuestos macrociclicos. | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2022007629A (es) | Combinaciones. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12017501882A1 (en) | Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| WO2018005444A3 (en) | Methods for treating cancer | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression |